Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
A phase 2 trial of Abexinostat in follicular lymphoma, run by Xynomic Pharmaceuticals, Inc., active and no longer recruiting.
Overview
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma is a phase 2 interventional study registered as NCT03600441 by Xynomic Pharmaceuticals, Inc., with 139 participants planned, started 2018-08-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: Abexinostat. Conditions listed: Follicular Lymphoma. No results are recorded here; the registry entry is the source.
Setting
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Phase
Phase 2
Sponsor
Xynomic Pharmaceuticals, Inc.
Registry
Enrolled
139